Clearside Biomedical, Inc. (CLSD)
NASDAQ: CLSD · Real-Time Price · USD
0.3853
-0.0100 (-2.53%)
Aug 27, 2025, 3:51 PM - Market open
Clearside Biomedical Stock Forecast
CLSD's stock price has decreased by -60.27% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 3 analysts that cover Clearside Biomedical stock have a consensus rating of "Hold" and an average price target of $4.33, which forecasts a 1,023.80% increase in the stock price over the next year. The lowest target is $3.00 and the highest is $5.00.
Price Target: $4.33 (+1,023.80%)
Analyst Consensus: Hold
* Price targets were last updated on Jul 18, 2025.
Analyst Ratings
The average analyst rating for Clearside Biomedical stock is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 0 | 0 |
| Buy | 2 | 2 | 2 | 2 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 3 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 5 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Chardan Capital | Chardan Capital | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Jul 18, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy → Hold Downgrades $5 | Strong Buy → Hold | Downgrades | $5 | +1,197.69% | Jul 18, 2025 |
| Needham | Needham | Strong Buy → Hold Downgrades $3 | Strong Buy → Hold | Downgrades | $3 | +678.61% | Jul 17, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $6 → $5 | Strong Buy | Maintains | $6 → $5 | +1,197.69% | May 23, 2025 |
| JMP Securities | JMP Securities | Buy Reiterates $5 | Buy | Reiterates | $5 | +1,197.69% | May 16, 2025 |
Financial Forecast
Revenue This Year
3.30M
from 1.66M
Increased by 98.20%
Revenue Next Year
10.35M
from 3.30M
Increased by 213.77%
EPS This Year
-0.22
from -0.47
EPS Next Year
-0.09
from -0.22
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 3.7M | 21.3M | |||
| Avg | 3.3M | 10.3M | |||
| Low | 2.7M | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 120.9% | 546.0% | |||
| Avg | 98.2% | 213.8% | |||
| Low | 64.9% | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.20 | -0.01 | |||
| Avg | -0.22 | -0.09 | |||
| Low | -0.24 | -0.17 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.